Seeking Alpha

More on GSK-Human Genome deal. GSK (GSK +0.2%) finally gets HGS (HGSI +3%) after a protracted...

More on GSK-Human Genome deal. GSK (GSK +0.2%) finally gets HGS (HGSI +3%) after a protracted fight and increasing the offer from $2.8B or $13/share. While the deal is worth $3.6B on an equity basis, it's valued at $3B net of cash and debt. The $14.25/share offer is almost double HGSI's closing price of $7.17 on 18 April, just prior to GSK's initial proposal being made public. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|